Abstract
Women with advanced heart failure (HF) are underrepresented in trials of short-term and durable mechanical circulatory support although they derive similar benefit. In acute HF, intensive medical and interventional therapies are effective but underutilized. The smaller, newer generation, left ventricular assist devices (LVADs) have increased the feasibility of durable support in women. Women frequently present late, with more comorbidities, emphasizing the need for timely referral. Compared with men, the stroke risk is higher in women with an LVAD. Increased representation in clinical trials and a better understanding of the psychosocial issues affecting women is essential.
Original language | English (US) |
---|---|
Pages (from-to) | 97-107 |
Number of pages | 11 |
Journal | Heart Failure Clinics |
Volume | 15 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Externally published | Yes |
Keywords
- Advanced heart failure
- Cardiogenic shock
- Left ventricular assist device
- Percutaneous mechanical circulatory support
- Women
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine